Literature DB >> 24618609

Loss of SMAD4 protein expression is associated with high tumor grade and poor prognosis in disseminated appendiceal mucinous neoplasms.

Jon M Davison1, Douglas A Hartman, Aatur D Singhi, Haroon A Choudry, Steven A Ahrendt, Amer H Zureikat, Lekshmi Ramalingam, Marina Nikiforova, Reetesh K Pai.   

Abstract

The distinction between low-grade and high-grade disseminated appendiceal mucinous neoplasms is of critical importance in assessing prognosis and guiding patient therapy. SMAD4 encodes a protein that is a central component of the TGFβ signal transduction pathway, and loss of SMAD4 expression has been associated with poor prognosis in carcinomas of the gastrointestinal tract. We reviewed the clinicopathologic and molecular features of 109 disseminated appendiceal mucinous neoplasms identified over an 8-year period at our institution in an attempt to: (1) correlate SMAD4 immunohistochemical expression with tumor grade; and (2) assess the prognostic significance of SMAD4 expression in predicting overall survival. Compared with tumors demonstrating preserved SMAD4 expression, tumors with loss of SMAD4 expression more frequently exhibited high cytologic grade (85% vs. 50%, P=0.035), high cellularity (100% vs. 45%, P<0.001), and destructive invasion (100% vs. 55%, P=0.001). SMAD4 expression significantly correlated with overall tumor grade (P=0.003): all 13 tumors with loss of SMAD4 expression were high grade, whereas all 42 low-grade tumors displayed preserved SMAD4 expression. A significantly higher proportion of tumors with loss of SMAD4 immunohistochemical expression demonstrated loss of heterozygosity at chromosome 18q (38%) compared with tumors with preserved SMAD4 expression (11%) (P=0.049), suggesting that loss of SMAD4 expression is due to genomic deletion in a high proportion of cases. Patients with SMAD4-negative tumors had significantly worse overall survival in comparison with patients with preserved SMAD4 expression (log rank P=0.023). However, our multivariable analysis found that SMAD4 expression was not independent of overall tumor grade in predicting overall survival. Our results indicate that loss of SMAD4 immunohistochemical expression is associated with loss of heterozygosity at chromosome 18q and is always associated with aggressive histologic features in disseminated appendiceal mucinous neoplasms. SMAD4 immunohistochemistry may be a useful ancillary study in select cases of disseminated appendiceal neoplasia, in which the distinction between low-grade and high-grade tumors is difficult.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24618609     DOI: 10.1097/PAS.0000000000000194

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  7 in total

Review 1.  New insights in the pathology of peritoneal surface malignancy.

Authors:  Norman John Carr
Journal:  J Gastrointest Oncol       Date:  2021-04

2.  Prognostic Roles of ZNF703 and SMAD4 Expression in Patients with Papillary Thyroid Cancer and Association with Nodal Metastasis.

Authors:  Asmaa Hussein Mohamed; Ola A Harb; Shereen El Shorbagy; Rawda Balata; Mohamed Farouk Amin; Osama Abd-Elaziz
Journal:  Indian J Surg Oncol       Date:  2022-02-15

Review 3.  The Landmark Series: Appendiceal Primary Peritoneal Surface Malignancy.

Authors:  Alexandra Gangi; Rupen Shah
Journal:  Ann Surg Oncol       Date:  2021-12-01       Impact factor: 5.344

4.  SMAD4 mutation correlates with poor prognosis in non-small cell lung cancer.

Authors:  Yue Wang; Qianqian Xue; Qiang Zheng; Yan Jin; Xuxia Shen; Mu Yang; Xiaoyan Zhou; Yuan Li
Journal:  Lab Invest       Date:  2020-12-10       Impact factor: 5.662

5.  Clinicopathological characterization of SMAD4-mutated intestinal adenocarcinomas: A case-control study.

Authors:  Xiaoyan Liao; Yansheng Hao; Xiaofei Zhang; Stephen Ward; Jane Houldsworth; Alexandros D Polydorides; Noam Harpaz
Journal:  PLoS One       Date:  2019-02-07       Impact factor: 3.240

6.  Unusual site of pseudomyxoma peritonei recurrence after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a case report of intraluminal disease manifestation in the small bowel.

Authors:  Paulien Rauwerdink; Lodewijk A A Brosens; Karin K van Diepen; Okan N Ghedri; Onno Kranenburg; Djamila Boerma; Arjen J Witkamp; Helma M U van Grevenstein
Journal:  World J Surg Oncol       Date:  2022-05-10       Impact factor: 3.253

7.  Carcinosarcoma with Choriocarcinomatous and Osteosarcomatous Differentiation in a Patient with Juvenile Polyposis Syndrome.

Authors:  Rafael Parra-Medina; Patricia López Correa; Julian Jiménez Moreno; Paula Moreno Lucero; Edgardo Yaspe; Fernando Polo
Journal:  Rare Tumors       Date:  2015-09-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.